JPMorgan Chase & Co. Decreases Stock Position in Capricor Therapeutics, Inc. $CAPR

Key Points

• JPMorgan Chase & Co. cut its position in Capricor by 45% in Q3, selling 155,390 shares and retaining 189,799 shares (about 0.42% of the company) valued at roughly $1.37 million.
• Insiders have been net sellers: the CFO sold 25,000 shares and a director sold 7,529, with insiders offloading 147,529 shares worth $4.51 million over the past three months while still owning 10.5% of the stock.
• Wall Street shows a consensus Moderate Buy (nine Buys, one Sell) with an average price target of $46.09 versus the current $31.60 quote; the company has a $1.82 billion market cap and a 52-week range of $4.30–$40.37.

JPMorgan Chase & Co. reduced its position in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 45.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 189,799 shares of the biotechnology company's stock after selling 155,390 shares during the period. JPMorgan Chase & Co. owned about 0.42% of Capricor Therapeutics worth $1,368,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in CAPR. Russell Investments Group Ltd. grew its position in Capricor Therapeutics by 122.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 2,786 shares during the period. Legal & General Group Plc grew its position in Capricor Therapeutics by 8.4% in the 2nd quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company's stock worth $410,000 after purchasing an additional 3,205 shares during the period. Rhumbline Advisers grew its position in Capricor Therapeutics by 7.3% in the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company's stock worth $531,000 after purchasing an additional 3,636 shares during the period. Farther Finance Advisors LLC bought a new stake in Capricor Therapeutics in the 3rd quarter worth approximately $28,000. Finally, Tower Research Capital LLC TRC grew its position in Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company's stock worth $67,000 after purchasing an additional 4,976 shares during the period. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Anthony Bergmann sold 25,000 shares of the business's stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $30.13, for a total transaction of $753,250.00. Following the completion of the sale, the chief financial officer owned 8,223 shares of the company's stock, valued at $247,758.99. The trade was a 75.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Karimah Es Sabar sold 7,529 shares of the business's stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $32.00, for a total transaction of $240,928.00. Following the sale, the director directly owned 7,529 shares of the company's stock, valued at approximately $240,928. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 147,529 shares of company stock valued at $4,509,940. Insiders own 10.50% of the company's stock.

Capricor Therapeutics Price Performance

Shares of CAPR stock opened at $31.60 on Thursday. Capricor Therapeutics, Inc. has a 1 year low of $4.30 and a 1 year high of $40.37. The firm has a fifty day moving average price of $27.91 and a 200-day moving average price of $19.63. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -13.98 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.11). Equities research analysts expect that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Wall Street Analysts Forecast Growth

CAPR has been the subject of a number of research analyst reports. Wall Street Zen downgraded shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, January 11th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Capricor Therapeutics in a research report on Monday, December 29th. Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the stock an "overweight" rating in a research report on Friday, March 13th. B. Riley Financial lifted their target price on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the stock a "buy" rating in a research report on Friday, March 13th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $60.00 target price on shares of Capricor Therapeutics in a research report on Tuesday, March 10th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $46.09.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.